SUPN250417P38000
- 0.00
- 0.000.00%
Supernus Pharmaceuticals Newsroom
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Promising Growth Prospects for Supernus Pharmaceuticals: Buy Rating Driven by Qelbree and Onapgo Market Opportunities
Multiple Insiders Sold Supernus Pharmaceuticals Shares Presenting Weak Signs For Investors
Piper Sandler Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals CEO Jack Khattar to Speak at Upcoming Investor Conferences in March 2025
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?
Supernus Pharmaceuticals' Earnings Call Highlights Growth and Challenges
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
Supernus Pharmaceuticals Price Target Maintained With a $36.00/Share by Cantor Fitzgerald
Supernus Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals(SUPN.US) to Hold Rating, Cuts Target Price to $36
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance